Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective.
about
Immunological assays for chemokine detection in in-vitro culture of CNS cellsStandardization of cytokine flow cytometry assaysAnemia in Chronic obstructive pulmonary disease: Prevalence, pathogenesis, and potential impactModeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cellsEnhanced fluorescence of proteins and label-free bioassays using aluminum nanostructuresSafety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial.Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)The role of laboratory medicine in healthcare: quality requirements of immunoassays, standardisation and data management in prospective medicine.Development of an enzyme immunoassay for a stable amidated analog of the hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro.Data quality in drug discovery: the role of analytical performance in ligand binding assays.Peptide impurities in commercial synthetic peptides and their implications for vaccine trial assessmentPrecision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides.A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE.Clinical Pharmacology and Translational Aspects of Bispecific AntibodiesMultiplex Immunosensor Arrays for Electrochemical Detection of Cancer Biomarker Proteins.Multiplexed serologic assay for nine anogenital human papillomavirus types.Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs.Measurement and quality control issues in multiplex protein assays: a case study.Immunoassay Methods and their Applications in Pharmaceutical Analysis: Basic Methodology and Recent Advances.Performance of multiplex cytokine assays in serum and saliva among community-dwelling postmenopausal women.Development and evaluation of a pseudovirus-luciferase assay for rapid and quantitative detection of neutralizing antibodies against enterovirus 71.Enzyme-linked immunosorbent assay for measuring antibodies to pneumococcal polysaccharides for the PNEUMOVAX 23 vaccine: assay operating characteristics and correlation to the WHO international assayDetection of the circulating antigen 14-3-3 protein of Schistosoma japonicum by time-resolved fluoroimmunoassay in rabbits.Microfluidic electrochemical immunoarray for ultrasensitive detection of two cancer biomarker proteins in serum.Biomarkers in drug discovery and development: from target identification through drug marketing.Generation of polyclonal antibody with high avidity to rosuvastatin and its use in development of highly sensitive ELISA for determination of rosuvastatin in plasmaSystematic verification of bioanalytical similarity between a biosimilar and a reference biotherapeutic: committee recommendations for the development and validation of a single ligand-binding assay to support pharmacokinetic assessmentsWhen close is not close enough: a comparison of endogenous and recombinant biomarker stability samples.Recognition of N-glycoforms in human chorionic gonadotropin by monoclonal antibodies and their interaction motifs.Hazards in chromatographic bioanalysis method development and applications.Electrochemical immunosensors for detection of cancer protein biomarkers.Interlaboratory evaluation of automated, multiplexed peptide immunoaffinity enrichment coupled to multiple reaction monitoring mass spectrometry for quantifying proteins in plasmaRelationships between inflammatory cytokine and cortisol responses in firefighters exposed to simulated wildfire suppression work and sleep restrictionBiomarker method validation in anticancer drug developmentStandardization of Hemagglutination Inhibition Assay for Influenza Serology Allows for High Reproducibility between Laboratories.The development and application of a high-sensitivity immunoassay for cardiac myosin-binding protein CA microfluidic electrochemiluminescent device for detecting cancer biomarker proteins.Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients.Confirmatory reanalysis of incurred bioanalytical samples.Methodologic issues in the validation of putative biomarkers and surrogate endpoints in treatment evaluation for systemic lupus erythematosus.
P2860
Q24794047-581B1756-0761-4F48-8DCF-8C1422BE6118Q24811983-B35464E1-8275-4727-9196-D232FF548EF1Q28084856-F82E5946-2330-480E-AFA5-BA901FC49804Q28477427-211C2A24-E793-4A09-AC7F-EA67BC61D420Q28748295-C2863E9E-46CE-42E8-AF74-80D6CD68E7CBQ30151079-27F0362B-6FA2-499B-8DA9-ECEE09D1803FQ30444086-393869AF-BEC8-444F-8B26-EE0E9EA39CA3Q30579392-51B2586C-184E-4C82-8C53-CD375B96852FQ30697376-5A5F4550-A96C-415B-84AD-F649C44ADD10Q30970805-E3836EE1-3F9D-4FBD-B1A1-35DCF3EC4EFEQ33310152-E3CE23FD-19EB-44C3-9A63-F03E62F43771Q33325811-7F6DDC80-B932-454F-938A-1272B6F5FEE9Q33624420-BC9A4FC0-C659-497A-86EC-8178E619707BQ33648086-6F893DB5-1A8D-4077-A4AA-9C6CA9A60054Q33764870-09AC2CCB-BD0B-4D72-807D-ACBE09F26506Q33825698-AF578E7D-4E80-4C2B-93CA-D4ECC775C924Q33847836-62465602-5298-4F36-8305-361CC466AA24Q34248964-CA44DEFC-A7BD-48B8-98DC-6C7758B9C11DQ34344761-559ACB53-1E4F-4E86-8BE6-F9D6085EE045Q34663573-C6F0C951-8860-4B74-8708-625E270C8CFFQ34765645-FD71AD59-F4A4-4D97-B15E-C0CD6F1BEAD9Q34975051-4FFEF135-C53D-4439-9C10-8F3BFF4C6EA9Q35047756-AA5962C0-3364-4E3B-AA84-93A669A81D54Q35061782-959A0ED8-8406-4723-8A93-D23DD55D2E84Q35118033-841C46C9-80D4-42E5-930C-9ABC21AD2779Q35145705-413011F4-2D69-4F3A-94F2-6247A1FC922AQ35318355-DADE6C17-81A9-413B-ACD8-739FE8DA7929Q35674203-8FEF62F1-8656-4764-AA9C-6647C94E6695Q36050006-37C2DD50-C57B-4938-A7A3-A5DA1FE37510Q36151681-8AB23D54-C059-4268-9316-253EEAF75C96Q36195062-3E554B8C-D480-4739-8400-FB47BDB60781Q36209072-E4729F12-9783-49A3-B473-43D1E3B7E8EBQ36357515-EF6C900D-2A94-4C69-9D85-89ADDD01AB37Q36484621-8115D63B-4E63-4CA2-8DD5-8994ADBAF658Q36665657-39F9CA09-E316-4352-8D9C-8A3C6C519EC5Q36698261-3DB47B97-16B2-4285-A9EA-34A4FC558229Q36724643-9380851B-DEAD-481F-A615-2D0AC32D0BF0Q37020244-145A0FFE-2382-4D2A-8198-F4C1113E4EF9Q37048572-806EB789-10BD-424E-B329-F10941BABAE1Q37101364-E2A0EEFA-3E76-4B30-8765-188A0FC932A8
P2860
Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective.
@ast
Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective.
@en
type
label
Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective.
@ast
Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective.
@en
prefLabel
Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective.
@ast
Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective.
@en
P2093
P1476
Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective.
@en
P2093
Bowsher RR
DeSilva BS
Findlay JW
Nordblom GD
P304
P356
10.1016/S0731-7085(99)00244-7
P577
2000-01-01T00:00:00Z